PHILADELPHIA (CNN) — In a new document posted ahead of a key meeting of the U.S. Food and Drug Administration’s vaccine advisers, Pfizer says its vaccine is safe and 90.7% effective against symptomatic COVID-19 in children ages 5 to 11. In the trial, which included around 2,000 children, there were three COVID-19 cases among the group that received the vaccine and 16 cases in the placebo group. In the trial, twice as many children received the vaccine as the placebo.
Pfizer/BioNTech are seeking FDA emergency use authorization of a two-dose regimen of their 10-microgram dose for children ages 5 to 11. The two doses would be administered three weeks apart.READ MORE: First Confirmed Cases Of COVID-19 Omicron Variant Reported In Philadelphia, New Jersey
Last month, Pfizer released details of a Phase 2/3 trial that showed its COVID-19 vaccine was safe and generated a “robust” antibody response in children ages 5 to 11. The trial included 2,268 participants ages 5 to 11. Participants’ immune responses were measured by looking at neutralizing antibody levels in their blood and comparing those levels to a control group of 16- to 25-year-olds who were given a two-dose regimen with the larger 30-microgram dose. Pfizer said the levels compared well with older people who received the larger dose, demonstrating a “strong immune response in this cohort of children one month after the second dose.”READ MORE: Family Of Fallen Delaware County Firefighter Has Mortgage Fully Paid Off
The FDA’s Vaccines and Related Biological Products Advisory Committee is scheduled to meet October 26 to discuss whether to recommend the vaccine for authorization for those ages 5 to 11.
If authorized, this would be the first COVID-19 vaccine for younger children. The Pfizer/BioNTech vaccine is approved for people age 16 and older and has an EUA for people ages 12 to 15.MORE NEWS: Mother Of Ahmir Jones, Teen Killed Protecting Girlfriend During Robbery Near Temple University, Speaks Out
The-CNN-Wire™ & © 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.